Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

London pre-open: Stocks seen lower as investors mull GDP data

(Sharecast News) - London stocks were set to fall at the open on Friday following a downbeat session on Wall Street, as investor mull the latest UK GDP data. The FTSE 100 was called to open 26 points lower at 7,885.

Figures out earlier from the Office for National Statistics showed the UK narrowly avoided a technical recession at the end of last year, after the economy stagnated in the last quarter of 2022.

GDP fell 0.5% in December following growth of 0.1% in November and 0.55% in October. December's print was dragged down by a 0.8% decline in the services sector, which recorded falls in health, education, transport and storage, arts and entertainment.

However, it was not enough to push the quarterly data into negative territory, and GDP was 0.0% in the three months to December, following a decline of 0.3% in November.

The definition of a recession is two consecutive quarters of contraction.

Sophie Lund-Yates, lead equity analyst at Hargreaves Lansdown, said: "While the absence of an official label will be seen as a victory, there's an argument to say the can has simply been kicked further down the road. The ramifications for consumers are also tough: around 7m households are still expected to struggle to pay energy and food bills, technical recession or not."

In corporate news, FirstGroup said it had been granted a two-year extension for its South Western Railway franchise, by the UK government.

The contract, which began in May 2021, will now run until May 25 2025 on existing terms, the company said.

Drugmaker GSK's mismatch repair-deficient recurrent or advanced endometrial cancer treatment has been granted full approval by the US Food and Drug Administration.

GSK said Jemperli's approval comes hot on the heels of long-term outcome results from its GARNET phase I trial, which demonstrated an overall response rate of 45.4%.

Share this article

Related Sharecast Articles

London midday: FTSE touch firmer after jobs data, Pill comments
(Sharecast News) - London stocks were still just a touch firmer by midday on Tuesday as investors mulled the latest jobs data and comments from Bank of England chief economist Huw Pill.
London open: Stocks nudge up as investors mull jobs data
(Sharecast News) - London stocks were just a touch higher in early trade on Tuesday as investors mulled conflicting UK jobs data.
London pre-open: Stocks seen down as investors mull jobs data
(Sharecast News) - London stocks were set to edge lower at the open on Tuesday as investors mulled data showing the UK jobs market is cooling.
London close: Stocks take a breather after last week's surge
(Sharecast News) - London's stock markets ended the day in negative territory on Monday, with investors taking a breather following a six-day winning streak that propelled the FTSE 100 to a new all-time high.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.